197 related articles for article (PubMed ID: 8782444)
1. HIV-1 Tat protein as a potential AIDS vaccine.
Goldstein G
Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
[No Abstract] [Full Text] [Related]
2. HIV-1 Tat vaccines.
Ensoli B; Cafaro A
Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
[No Abstract] [Full Text] [Related]
3. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
4. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
[TBL] [Abstract][Full Text] [Related]
7. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
[TBL] [Abstract][Full Text] [Related]
8. Tat-neutralizing antibodies in vaccinated macaques.
Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
[TBL] [Abstract][Full Text] [Related]
9. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
11. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
12. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
13. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
[TBL] [Abstract][Full Text] [Related]
14. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
15. Ability to generate synthetic peptides that immunologically mimic HIV-1 tat regulatory protein.
Biquard JM; M'Bika JP; Krsmanovic V; Achour A
AIDS; 2003 Sep; 17(13):2001-2. PubMed ID: 12960840
[No Abstract] [Full Text] [Related]
16. Full-length HIV-1 Tat protein necessary for a vaccine.
Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
[TBL] [Abstract][Full Text] [Related]
17. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
Re MC; Gibellini D; Vitone F; La Placa M
New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
[TBL] [Abstract][Full Text] [Related]
18. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
Gallo RC
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
[No Abstract] [Full Text] [Related]
19. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
Rodman TC; To SE; Hashish H; Manchester K
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
[TBL] [Abstract][Full Text] [Related]
20. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
